New Delhi : Supriya Lifescience Ltd (SLL), a leader in the pharmaceutical industry, has taken another significant step on its ambitious growth trajectory with the inauguration of its new multipurpose Active Pharmaceutical Ingredients (APIs) production block, Module E, at the Lote Parshuram site. The facility, developed with an investment of approximately ₹120 crore, adds a substantial capacity of 335 kiloliters to the company’s operations. This expansion boosts our Lote Parshuram capacity by over 55%, increasing it from 597 KLPD to 932 KLPD.
The new production block is designed to support SLL’s strategic focus on expanding its R&D capabilities and scaling up its pipeline of innovative products. Several new products in niche therapeutic areas are nearing the commercialization stage, reinforcing SLL’s commitment to achieving a leadership position in these markets through efficient processes and backward integration.
Some of the salient features of the facility are:
- The facility is tailored to support the company’s backward integration model, ensuring economies of scale and a competitive edge
- Spread across 5,000 square meters and structured over four levels, the facility enables efficient operations and safe workflows
- The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL
- The design leverages gravity-based process flows to enhance safety, maintain product integrity, and optimize efficiency
- Incorporating closed-system handling at critical stages, the facility is equipped with process control automation systems and material handling systems to ensure compliance with the latest quality standards
- The facility is equipped to handle a variety of unit processes and operations, making it adaptable to future needs.
Dr. Satish Wagh, Executive Chairman & WTD, Supriya Lifescience Ltd, commenting on the occasion, said, – “We are excited to inaugurate our new manufacturing Module E block today. With the latest technologies and our team’s dedication, we are poised to elevate product quality, ensure efficiency through backward integration, and meet growing global demand. Module E is a testament to our strategic focus on innovation and sustainability, serving as a key driver of growth while reducing dependence on imports. As SLL continues to strengthen its infrastructure and expand its product portfolio, the company remains dedicated to setting new benchmarks in the pharmaceutical industry and delivering value to its stakeholders”